CORNEA

World's Most Influential People in Ophthalmology

Retrieved on: 
Thursday, May 9, 2024
Education, FDA, Bascom Palmer Eye Institute, Genetics, Teaching, Surgeon, Paratriathlon, Neuro-ophthalmology, Leach, Strabismus, Cataract, Knowledge, Bascom H. Palmer, Gedde, Eye, DRS, Retina, Vision science, Quality of life, Publication, Research, Bevacizumab, Artificial intelligence, Suture, Health, M.A, Choroideremia, Medeiros, Vance DeGeneres, University, Retinitis pigmentosa, Epidemiology, American Journal, Power, Patient, Physician, Uveitis, Glaucoma, Nursing

MIAMI, May 9, 2024 /PRNewswire/ -- Fifteen Bascom Palmer Eye Institute physicians were selected for the 2024 Power List, a prestigious selection of the world's 100 most influential people shaping the future of eye care, as published by The Ophthalmologist magazine. Drs. Eduardo C. Alfonso, Kendall Donaldson, Hilda Capó, Janet Davis, Harry Flynn, Anat Galor, Steven Gedde, Ranya Habash, Carol Karp, Jaclyn Kovach, Byron Lam, Felipe Medeiros, Richard Parrish, Philip Rosenfeld, and Sonia Yoo were named to the 2024 Power List. Bascom Palmer Eye Institute is the Department of Ophthalmology for the University of Miami Miller School of Medicine and UHealth – University of Miami Health System.

Key Points: 
  • Bascom Palmer Eye Institute is the Department of Ophthalmology for the University of Miami Miller School of Medicine and UHealth – University of Miami Health System.
  • From cutting-edge treatments to groundbreaking research, these doctors are pushing boundaries and setting new standards in ophthalmology."
  • Alfonso, the holder of the Kathleen and Stanley J. Glaser Chair in Ophthalmology, was also named to the Ophthalmologist Power Lists 2014, 2016, 2018, 2022, and 2023.
  • Holder of the John T. Flynn Chair in Ophthalmology, Hilda Capó, M.D., specializes in pediatric ophthalmology and adult strabismus.

Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Retrieved on: 
Thursday, May 9, 2024
Pain, Cell, Telecanthus, Endothelium, Tissue, Paratriathlon, DED, Eye, ARVO, Disease, Therapy, Patient, SWAP, Irritation, Regeneration, Annual general meeting, Vaccine

“These early results are important as Fuchs’ Endothelial Cell Dystrophy and Dry Eye Disease are severe diseases with few effective treatments available.

Key Points: 
  • “These early results are important as Fuchs’ Endothelial Cell Dystrophy and Dry Eye Disease are severe diseases with few effective treatments available.
  • The company evaluated a therapeutic approach to stimulate endothelial cell proliferation as human corneal endothelial cells have a limited capacity to regenerate.
  • The lead molecule, a Surrozen Fzd 1/2/7 SWAP antibody, increased proliferation of endothelial cells in vitro in human cells.
  • Currently, there is no epithelial regeneration strategy available as treatment usually consists of anti-inflammatory topical eye drops and tear replacements.

Surrozen Provides First Quarter 2024 Financial Results and Business Update

Retrieved on: 
Wednesday, May 8, 2024
Respiratory Research, Telecanthus, Liver disease, Boehringer Ingelheim, Publication, Research, Partnership, Development, Administration, ARVO, Therapy, Pulmonary fibrosis, Retina, Patient, Liver, Eye, Fibrosis, Regeneration, SWAP

SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today provided first quarter 2024 financial results and business updates.

Key Points: 
  • Financial Results for the First Quarter Ended March 31, 2024
    Cash Position: Cash and cash equivalents were $27.3 million as of March 31, 2024, compared to $36.0 million as of December 31, 2023.
  • However, inclusive of proceeds from a financing completed in April 2024, the proforma cash for March 31, 2024 would be $43.2M.
  • Restructuring: Restructuring charges for the first quarter ended March 31, 2024 were zero, as compared to $1.2 million for the same period in 2023.
  • Net Loss: Net loss for the first quarter ended March 31, 2024 was $8.8 million, as compared to $14.3 million for the same period in 2023.

STAAR Surgical Announces Milestone Strategic Agreement in U.S. with IQ Laser Vision

Retrieved on: 
Tuesday, May 7, 2024
Optical, Health, Surgery, Medical Devices, Education, Near-sightedness, Left, Presbyopia, EVO, Refractive surgery, Cataract, PIB, STAAR, Surgeon, Nave, MD, Quality, ICL, Contact, Chairperson, Lens, ASCRS, Eye, Society, Athlete, Multimedia, Marketing, SMILE, Astigmatism, Growth, Telescopic sight

View the full release here: https://www.businesswire.com/news/home/20240507036972/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240507036972/en/
    Tom Frinzi, Chair of the Board, President and CEO, STAAR Surgical (Left) and Dr. Robert T. Lin, founder and surgeon, IQ Laser Vision (Right).
  • (Photo: Business Wire)
    IQ Laser Vision will make EVO ICL lenses a primary option for patients seeking surgical vision correction within the range of -3D to -20D, as part of its comprehensive refractive offering.
  • IQ Laser Vision intends to nearly double its volume in EVO ICLs over the course of the next 12 months.
  • Today, we’re thrilled to announce that IQ Laser Vision has joined our U.S. Highway 93 program with the largest agreement for EVO ICL in the U.S. thus far.

Eyemart Express' Expert Insights on Dry Eyes for Healthy Vision Month

Retrieved on: 
Monday, May 6, 2024
Tears, Climate, Health, Vascular disease, Paratriathlon, Blinking, Diet, Eye, Work, Salmon, Diagnosis, Allergy, Vein, Artery

FARMERS BRANCH, Texas, May 6, 2024 /PRNewswire/ -- May is Healthy Vision Month, and Eyemart Express is taking the opportunity to shed light on an often overlooked yet prevalent issue: dry eyes. Approximately 50.2 million Americans suffer from dry eyes, and that number is increasing with our growing dependence on technology and looking screens for work and entertainment all day. The national optical retailer is partnering with Dr. Lavar Kofoed, an experienced eye doctor with practices across Utah and Idaho, to build awareness about dry eyes, including symptoms and easy treatments to keep the eyes healthy.

Key Points: 
  • The national optical retailer is partnering with Dr. Lavar Kofoed , an experienced eye doctor with practices across Utah and Idaho, to build awareness about dry eyes, including symptoms and easy treatments to keep the eyes healthy.
  • Getting a formal diagnosis from an eye doctor is an important first step in treating dry eyes.
  • When it comes to diagnosing and treating dry eyes, Dr. Kofoed recommends starting with an annual eye exam.
  • "It is necessary to support the pillars for wellness to treat and prevent dry eyes outside of an eye doctor's office."

Excision BioTherapeutics to Present Positive Data from its HSV-1 Keratitis Program, EBT-104, at the ASGCT 2024 Annual Meeting

Retrieved on: 
Monday, April 22, 2024
Corneal opacity, AAV2, Nanopore, Rabbit, Immortalised cell line, Genomics, LTR, CRISPR, Genetic engineering, Abraxis BioScience, Infection, Gene, RNA, Recurrence, HeLa, Paratriathlon, Cell, HSK, AAV, Vero cell, Research, Pterygopalatine ganglion, FACS, PCR, Disease, DNA, Therapy, Viral load, HIV-1, Society, CDS, Gag, ICP0, Genome, Herpes simplex keratitis, LAT, Orientation, Annual general meeting, Edema, Valaciclovir, SAN, Vaccine

Herpes Simplex Keratitis (HSK), caused by the infection of herpes simplex virus type 1 (HSV-1) in the cornea, is a major cause of blindness worldwide.

Key Points: 
  • Herpes Simplex Keratitis (HSK), caused by the infection of herpes simplex virus type 1 (HSV-1) in the cornea, is a major cause of blindness worldwide.
  • Although current anti-HSV-1 therapies interfere with viral DNA replication, they do not eliminate HSV-1 reservoirs or prevent recurrence.
  • CRISPR/Cas-mediated gene editing can potentially address the underlying causes of the disease by directly eliminating the latent HSV-1 reservoirs.
  • The 440 guide RNA pairs formed with these 42 PlmCasX guide RNAs were tested in tissue culture for DNA excision efficiency.

Bausch + Lomb Announces Presentation of New Data at the Association for Research in Vision and Ophthalmology Annual Meeting

Retrieved on: 
Monday, April 29, 2024
Vitamins, Supplements, Other Health, Retail, Other Science, Pharmaceutical, Research, Optical, Convenience Store, Medical Devices, Discount, Variety, Science, Clinical Trials, Medical Supplies, General Health, Surgery, Other Retail, Health, Specialty, Hydrogen, Verge, PAF, Frontiers Media, Efficacy, Safety, Trial of the century, Bausch & Lomb, MD, Erythritol, Development, Natural language, Convention (norm), Telecanthus, Research and development, Hosten, Toxicity, Comparison, Wood drying

The posters highlight the results of studies evaluating consumer, pharmaceutical, surgical and vision care products from the company’s broad eye care portfolio, as well as pipeline innovations.

Key Points: 
  • The posters highlight the results of studies evaluating consumer, pharmaceutical, surgical and vision care products from the company’s broad eye care portfolio, as well as pipeline innovations.
  • “A Natural Language Processing Approach to Identify Patients with Uveitic Macular Edema in the IRIS® Registry.” Jin et al.
  • “Clinical Evaluation of a Multi-Ingredient Oral Supplement on Dry Eye Symptoms and Tear Volume.” Barbour et al.
  • “Impact of Pupil Size on Vision Performance of a New Multifocal Daily Disposable Contact Lens.” Reindel et al.

Penn Highlands Healthcare Urges the Community: Help Save Lives. Become an Organ Donor

Retrieved on: 
Thursday, April 11, 2024
Kidney disease, Cancer, Lupus nephritis, Kidney, Hospital, Transplant, Travel, Nausea, Cardiology, HAP, Surgeon, DuBois, Pennsylvania, Life, Friends, Autoimmune disease, Family, Nursing, Eye, Dialysis, DLA, Social, Lupus, Quality of life, Pharmacist, Dentistry

She cannot travel far from her dialysis provider as she awaits a donor kidney.

Key Points: 
  • She cannot travel far from her dialysis provider as she awaits a donor kidney.
  • Eight lives can be saved by one organ donor; and, one tissue donor can heal 75 lives.
  • You can help people like Lisa who are waiting for an organ, eye or tissue donation by becoming a donor.
  • You can also become a donor when you renew your driver’s license in person, or online at dmv.pa.gov .

How a new drug prototype regenerates lung tissue

Retrieved on: 
Wednesday, April 10, 2024
Mortality, FDA, Idiopathic pulmonary fibrosis, Scripps Research, National library, National academy, Mouse, Cell, Kidney, World Health Organization, ReFrame, Research, IPF, Death, Respiratory disease, Doctor of Philosophy, DPP4, Rest, B cell, Human, COVID-19, Lung, Regenerative medicine, Biology, Heart failure, Clinical trial, Harvard University, Growth, Disease, Chronic obstructive pulmonary disease, Pharmaceutical industry

LA JOLLA, Calif., April 10, 2024 /PRNewswire/ -- Pulmonary diseases are a leading cause of morbidity and mortality worldwide. For many progressive lung diseases like idiopathic pulmonary fibrosis (IPF), a key issue is a low supply of new stem cells to repair and reverse damage. These cells are responsible for regenerating and increasing the growth of healthy tissue—without them, lung function decreases and a range of severe illnesses can take hold.

Key Points: 
  • "We chose the lung because the stem cell population of the lower airway doesn't regenerate as effectively as one ages."
  • However, there currently are no available treatment options that regenerate damaged lung tissue.
  • To see whether existing drug mechanisms could increase growth of lung stem cells, the team turned to ReFRAME , a drug repurposing library built by Calibr-Skaggs.
  • While NZ-97 is a prototype drug, it's chemically similar to CMR316, Calibr-Skagg's drug that will be entering a phase 1 clinical trial in a few months.

Chromocell Issues Letter to Stockholders from Chief Executive Officer

Retrieved on: 
Tuesday, April 9, 2024
Erythromelalgia, Consultant, Toxicity, ChromeOS, Abrasion (medical), Letter, Uveitis, Growth, Opioid, Neuropathic pain, Incidence, Physiology, Patient, NAV, Mortality, IPO, Human, Rash, Outline, Lawyer, Annual report, CHRO, PRK, Pain, Glaucoma, NSAID, Therapy, Family, Photorefractive keratectomy, FDA, Liver, Food, Pharmaceutical industry

We transferred $2.2 million in liabilities to Chromocell Corporation in exchange for 2,600 shares of Series C Convertible Redeemable Preferred Stock (“Series C Preferred Stock”).

Key Points: 
  • We transferred $2.2 million in liabilities to Chromocell Corporation in exchange for 2,600 shares of Series C Convertible Redeemable Preferred Stock (“Series C Preferred Stock”).
  • Our CEO has agreed to further defer a considerable portion of his accrued compensation, affirming the belief in Chromocell’s mission.
  • We truly feel that our IPO and recent therapeutic development activities have positioned Chromocell for long term growth and success.
  • I wish to thank you for your support and remain a resource to each of you as we move forward.